Jolyon Martin is co-founder and Head of Business Development for PetMedix, a biotech start-up based in Cambridge. PetMedix are developing novel veterinary medicines, targeting a range of diseases in dogs and cats. The company is a spin-out of the research that Jolyon carried out in his PhD in the lab of Professor Allan Bradely at the University of Cambridge.
This project started as a good scientific idea, and is now a company of 38 people that has raised $13M to date and is continuing to grow and thrive. In January 2021 PetMedix announced a partnership with Boehringer Ingelheim Animal health, a project that Jolyon lead on. For his work at PetMedix, Jolyon was recently named one of the '30 under 30' in Europe for Science and Healthcare by Forbes Magazine.